Background: ATP13A2 Biology and Function

ATP13A2 (ATPase 13A2) is a member of the P5-type ATPase subfamily, a group of evolutionarily conserved cation-transporting transmembrane proteins. The human ATP13A2 gene encodes a large, multi-pass transmembrane protein that resides predominantly on the lysosomal membrane, where it is believed to regulate cation homeostasis — including zinc, manganese, and possibly other divalent metal ions — within the lysosomal lumen.

ATP13A2 plays a critical role in maintaining lysosomal integrity and autophagy-lysosome pathway function. It supports the clearance of damaged proteins and organelles, contributing to the overall proteostasis network within neurons. Impaired ATP13A2 activity leads to lysosomal dysfunction, accumulation of autophagic vacuoles, mitochondrial fragmentation, and ultimately neuronal cell death — hallmarks observed in several neurodegenerative conditions.

The gene is also referred to as PARK9 in the context of inherited Parkinsonism, reflecting its designation as a locus associated with familial Parkinson's disease. Research using recombinant ATP13A2 protein has helped illuminate the structural and enzymatic basis of its transport activity and disease-associated loss of function.

Disease Relevance: Kufor-Rakeb Syndrome and Parkinson's Disease

Homozygous or compound heterozygous loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of juvenile-onset Parkinsonism. KRS is characterized by early-onset Parkinsonism, pyramidal degeneration, supranuclear upgaze paresis, and in some cases dementia. The identification of ATP13A2 mutations as causative in KRS established the PARK9 locus and highlighted lysosomal dysfunction as a central pathogenic mechanism in Parkinson's disease spectrum disorders.

Beyond KRS, heterozygous variants in ATP13A2 have been associated with increased risk for sporadic Parkinson's disease and neuronal ceroid lipofuscinosis, further broadening its clinical significance. Research with recombinant ATP13A2 protein supports mechanistic studies aimed at understanding how specific mutations disrupt protein folding, lysosomal targeting, or catalytic activity, and how these defects drive neurodegeneration.

Because of its central role in neuronal autophagy and metal ion regulation, ATP13A2 is also investigated in the context of alpha-synuclein aggregation — a hallmark of Parkinson's disease — since compromised lysosomal function impairs alpha-synuclein clearance and promotes its toxic accumulation.

Research Applications of Recombinant ATP13A2 Protein

Recombinant Human ATP13A2 Protein (SKU: rp369112) is a versatile reagent suited for a range of in vitro research applications. Key uses include:

• Biochemical assays: Enzymatic activity assays to characterize ATPase catalytic function, including ATP hydrolysis assays and phosphoenzyme intermediate detection.
• Protein–protein interaction studies: Pull-down assays and co-immunoprecipitation experiments to identify binding partners within the lysosomal membrane complex or autophagy machinery.
• Structural studies: As an antigen or reference standard for structural biology approaches such as cryo-electron microscopy or X-ray crystallography.
• Antibody production and validation: As an immunogen or positive control for generating and validating ATP13A2-specific antibodies.
• Drug discovery screening: As a target protein in high-throughput screening assays for small molecules that modulate ATPase activity, relevant to therapeutic development for Parkinson's disease and related lysosomal storage disorders.
• Cell-free reconstitution: Reconstitution of transport activity in liposome-based systems to study cation transport mechanisms.

Researchers should consult the product datasheet for recommended storage conditions, buffer composition, and suggested working concentrations for specific assay formats.

Technical Considerations and Handling

As a recombinant membrane-associated protein, ATP13A2 presents specific handling considerations that researchers should observe to maintain protein integrity and activity:

• Storage: Recombinant proteins should generally be stored at –80 °C in single-use aliquots to prevent repeated freeze-thaw cycles, which can compromise structural integrity and enzymatic activity. Specific storage recommendations are provided on the product datasheet.
• Reconstitution: If supplied lyophilized, reconstitute gently using the recommended buffer. Centrifuge briefly after reconstitution to collect any undissolved material.
• Detergent considerations: As a transmembrane protein, stabilization with mild non-denaturing detergents (e.g., DDM, digitonin) or incorporation into lipid nanodiscs may be required for functional studies. Refer to the datasheet for specific guidance.
• Working concentrations: Optimize empirically for each application. Pilot experiments with a dilution series are recommended before committing to large-scale assays.
• Quality controls: Verify protein integrity by SDS-PAGE under reducing and non-reducing conditions, and confirm identity by Western blot using a validated anti-ATP13A2 antibody.

Always refer to the most current Certificate of Analysis (CoA) for lot-specific purity, concentration, and activity data.